Record Details

Majun-e-Suranjan and Habb-e-Azraqi are two Unani compound drugs that are effective and safe in cases of gout - An initial study

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Majun-e-Suranjan and Habb-e-Azraqi are two Unani compound drugs that are effective and safe in cases of gout - An initial study
 
Creator Verma, Radhey Shyam
Afridi, Rifat
Rehman, Shagufta
Ayub, Sadia
Qayyum, Zoha
Singh, Ravendra
Afza, Sheereen
Akhtar, Jamal
Khan, Asim Ali
 
Subject Gout
Unani compound drugs (Majun-e-Suranjan, Habb-e-Azraqi)
efficacy and safety
 
Description 708-716
Present study evaluated the therapeutic efficacy and safety of two Unani compound drugs Majun-e-Suranjan and Habb-e-Azraqi in cases of gout on modern scientific parameters viz., clinical, biochemical and haematological. This work was conducted at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2014-2019. 71 people were chosen from the pool of patients visiting the outpatient department (OPD). Patients received the Unani medicines Majun-e-Suranjan in a dose of 5.0 g and Habb-e-Azraqi in a dose of 1 pill (250 mg) twice daily after meals for a period of 56-days. One-way analysis of variance (ANOVA) was used for the analysis of data, and the statistical significance of the findings was determined by Dennett's test. The study reveals that the two Unani medicines are safe, non-toxic, and significantly relieve the symptoms of gouty arthritis. It is suggested to conduct more research among a large population.
 
Date 2023-12-20T10:48:18Z
2023-12-20T10:48:18Z
2023-12
 
Type Article
 
Identifier 0975-1068 (Online); 0972-5938 (Print)
http://nopr.niscpr.res.in/handle/123456789/63052
https://doi.org/10.56042/ijtk.v22i4.7187
 
Language en
 
Relation Int Cl23: A61K 36/00, A61K 9/00
 
Publisher NIScPR-CSIR,India
 
Source IJTK Vol.22(4) [October 2023]